Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia
Year: 2020
Type: article
Abstract: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004.
DOI: 10.17615/t1gh-4p30
Authors: Addington, Donald E., Rosenheck, Robert A., Lieberman, Jeffrey A., Mohamed, Somaia, McEvoy, Joseph P., Swartz, Marvin S., Stroup, Thomas Scott, Davis, Sonia M.
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1121004391, G8700482840
OpenAlex ID: W4300066621